Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any familial hypocalciuric hypercalcemia in which the cause of the disease is a mutation in the CASR gene.
Features include always present findings: Hypermagnesemia, Hypercalcemia, and Hypocalciuria; and rarely findings: Hypercalciuria. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 1 | Nephrolithiasis |
Digestive system | 1 | Pancreatitis |
CASR encodes calcium sensing receptor (1,078 aa). G-protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis. Highest expression in Kidney Medulla (18.1 TPM) and Pancreas (3.5 TPM).
Familial hypocalciuric hypercalcemia 1 is caused by mutations in the CASR gene on chromosome 3.
The CASR protein participates in CASR:CASR agonists pathway.
CASR is classified as a druggable target (Cell Surface, Clinically Actionable, Druggable Genome, and G Protein Coupled Receptor categories) with score 6.1.
Genetic testing for CASR is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for familial hypocalciuric hypercalcemia 1 has been reported in the published literature.
Phenotype severity distribution: 3 always present features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
No clinical trials have been registered for familial hypocalciuric hypercalcemia 1.
38 publications have been identified in PubMed for familial hypocalciuric hypercalcemia 1. Research spans Case Report / Case Series (47%), Basic Science / Preclinical (24%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 18 | 47% |
Laboratory research | 9 | 24% |
Research summaries | 4 | 11% |
Testing and diagnosis research | 3 | 8% |
Clinical study results | 2 | 5% |
New treatment approaches | 2 | 5% |
Nava Suarez CC (2026). [PMID: 29083672](https://pubmed.ncbi.nlm.nih.gov/29083672/). *Unknown Journal*. [Review / Meta-Analysis]
Kołbuc M (2026). [PMID: 41501259](https://pubmed.ncbi.nlm.nih.gov/41501259/). *Pediatric nephrology (Berlin, Germany)*. [Gene Therapy / Novel Therapeutics]
Tian Y (2026). [PMID: 41624914](https://pubmed.ncbi.nlm.nih.gov/41624914/). *Genes & diseases*. [Basic Science / Preclinical]
Chondrogianni ME (2026). [PMID: 40760326](https://pubmed.ncbi.nlm.nih.gov/40760326/). *Hormones (Athens)*. [Review / Meta-Analysis]
Kou L (2026). [PMID: 41920387](https://pubmed.ncbi.nlm.nih.gov/41920387/). *Endocrine*. [Clinical Trial Publication]
Tao X (2026). [PMID: 41852233](https://pubmed.ncbi.nlm.nih.gov/41852233/). *J Int Med Res*. [Case Report / Case Series]
Yatsuga S (2026). [PMID: 42006556](https://pubmed.ncbi.nlm.nih.gov/42006556/). *Bone Rep*. [Case Report / Case Series]
Kopanos S (2026). [PMID: 42035203](https://pubmed.ncbi.nlm.nih.gov/42035203/). *J Med Case Rep*. [Case Report / Case Series]
Lin J (2026). [PMID: 42038813](https://pubmed.ncbi.nlm.nih.gov/42038813/). *JBMR Plus*. [Case Report / Case Series]
Woerde DJ (2026). [PMID: 41742529](https://pubmed.ncbi.nlm.nih.gov/41742529/). *Journal of veterinary internal medicine*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 1:06 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center